Here are factors shaping the 7MM cancer pain market

The introduction of emerging treatments is expected to drive growth.

The rising prevalence of cancer and the increasing awareness of cancer-associated pain are expected to drive growth in the cancer pain therapeutics market across the seven major markets (7MM), according to DelveInsight.

The market has seen no recent drug approvals, creating opportunities for pharmaceutical companies to develop and introduce new treatments, particularly those that are non-opioid-based.

Potential therapies are being investigated, whilst the introduction of emerging treatments with improved efficacy and a further improvement in the diagnosis rate is expected to drive market growth.

“As opioids continue to dominate cancer pain management, the anticipated launch of drugs like tetrodotoxin signals a major shift toward novel, nonopioid mechanisms,” the report said.

However, inadequate pain assessment, limited clinician training, and inconsistent healthcare reimbursement policies challenge the market.

Additionally, high treatment costs, limited access, therapy failures, and a shortage of healthcare professionals may impede growth.

7MM = US, Germany, France, Italy, Spain, UK, and Japan.